SequelSEC

Climb Bio, Inc. CLYM

Pharmaceutical Preparations · CIK 0001768446 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$67.88M
Fiscal year ended 2025-12-31
Free cash flow
-$54.54M
Fiscal year ended 2025-12-31

Climb Bio, Inc. (CLYM) reported net income of -$59.85M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Climb Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Climb Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$67.88M-$82.02M-$40.28M-$45.14M-$35.67M-$20.92M
Net income-$59.85M-$73.90M-$35.12M-$45.24M-$47.48M-$20.67M
Research & development$46.71M$14.34M$15.41M$26.21M$23.32M$8.77M
Weighted-average diluted sharesshares 67.81Mshares 48.16Mshares 26.99Mshares 26.31Mshares 12.26Mshares 2.19M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0
Diluted EPS$-0.88$-1.53$-1.30$-1.72$-4.24Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$21.17M$16.02M$24.86M$18.92M$12.35M$2.42M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Climb Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$35.68M$87.23M$93.11M$43.58M$46.92M$20.49M
Total assets$167.74M$217.19M$110.47M$134.99M$173.24M$24.63M
Current assets$105.85M$154.87M$110.26M$134.39M$148.25M$22.00M
Total liabilities$7.27M$5.31M$2.87M$6.28M$6.04M$3.06M
Current liabilities$6.98M$4.93M$2.83M$6.10M$6.03M$3.06M
Total equity incl. NCI$160.48M$211.88M$107.60M$128.72M$167.20M-$24.98M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$46.55M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.27M$705.00K$66.00K$750.00K$1.40M$1.09M

Cash flow

Climb Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$54.36M-$15.56M-$20.60M-$37.37M-$36.07M-$14.10M
Capital expenditures$186.00K$0UnavailableUnavailableUnavailableUnavailable
Investing cash flow$2.83M-$121.09M$68.98M$34.44M-$114.97M$8.08M
Financing cash flow-$21.00K$130.73M$841.00K$0$177.23M$4.92M
Net change in cash-$51.54M-$5.88M$49.53M-$3.34M$26.44M-$736.00K
Stock-based compensation$8.05M$5.56M$12.81M$6.99M$3.74M$707.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$97.00K$0UnavailableUnavailableUnavailableUnavailable

Derived

Climb Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$54.54M-$15.56MUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio15.16x31.41x38.92x22.04x24.58x7.18x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CLYM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.